Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22) - Image 1

£99.53

Springer Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)

Name: Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)
Brand: Springer
Price: 99.53 GBP
Availability: InStock

Diseases & Disorders

This is the usual price. Wait for it to drop, or tell us your number.

£100 today · usual range £0–£0 · best ever £21

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 627 days • 627 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 627 days • 8 price levels

Days at Price

Current Price

Price Analysis

Most common price: £99 (376 days, 60.0%)

Price range: £21 - £120

Price levels: 8 different prices over 627 days

Description

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will beuseful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.

Product Specifications

Brand: Springer
Format: Paperback
ASIN: 3030734420
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders
Domain: Amazon UK
Release Date: 25 July 2022
Listed Since: 27 June 2022

Barcode

No barcode data available

Springer Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)

This is the usual price. Wait for it to drop, or tell us your number.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)

Multiple Myeloma: Methods and Protocols: 1792 (Methods in Molecular Biology, 1792)

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Clinical Malignant Hematology

Multiple Myeloma and Other Plasma Cell Neoplasms: 0 (Hematologic Malignancies)

Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside

Springer Hematologic Cancers: Molecular Pathobiology to Therapy

Biology and Management of Multiple Myeloma (Current Clinical Oncology)

CHRONIC MYELOID LEUKEMIA FROM DAILY MA: From Daily Management to Complicated Issues (Cancer Etiology, Diagnosis and Treatments)

Diagnostic and Therapeutic Advances in Hematologic Malignancies: 99 (Cancer Treatment and Research, 99)

Hematologic Malignancies in Adults

Consulting Hematology and Oncology Handbook

Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy

Hematologic Malignancies: Methods and Techniques: 55 (Methods in Molecular Medicine, 55)

CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America: Volume 37-6 (The Clinics: Internal Medicine, Volume 37-6)

Multiple Myeloma and Related Disorders (Hodder Arnold Publication)

Tumors of the Bone Marrow (Atlas of Tumor Pathology, Series 4): No. 24

Oxford Textbook of Neurohaematology (Oxford Textbooks in Clinical Neurology)

Concise Manual of Hematology and Oncology

Innovative Leukemia and Lymphoma Therapy: 35 (Basic and Clinical Oncology)

Concise Manual of Hematology and Oncology

The MD Anderson Manual of Medical Oncology, Fourth Edition

Treatment of Multiple Myeloma and Related Disorders